Stefanie Zschaebitz

发表

Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

N. Halama, T. Weber, C. Springfeld, 2020 .

Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma

D. Jäger, S. Duensing, D. Teber, 2017 .

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

T. Holland-Letz, J. Debus, K. Herfarth, 2020, Nuklearmedizin.

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma

T. Holland-Letz, J. Debus, K. Herfarth, 2021, Cancers.

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, N. Agarwal, C. Szczylik, 2023, Journal of Clinical Oncology.

Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.

D. Jäger, A. Berger, G. Haag, 2015, World journal of gastroenterology.

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).

J. Carles, N. Agarwal, U. de Giorgi, 2023, Journal of Clinical Oncology.

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

B. Mellado, A. Hartmann, J. Haanen, 2020, Journal of Clinical Oncology.